TECENTRIQ (atezolizumab) + Nab-pac TNBC  Efficacy

NCCN Category 2A Preferred

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend atezolizumab (TECENTRIQ) in combination with nab-paclitaxel as a preferred option for patients with PD-L1 positive recurrent or metastatic triple-negative breast cancer (Category 2A preferred). 1*

mTNBC=metastatic triple-negative breast cancer; PD-L1=programmed death-ligand 1.
*Category 2A: based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Preferred intervention: interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability. Nab-paclitaxel (nab-pac) is also known as albumin-bound paclitaxel or paclitaxel protein-bound.
The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.